ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPersistent pharmacokinetic challenges to pediatric drug developmentRenal drug transporters and their significance in drug-drug interactionsRecent advances in understanding hepatic drug transportP-Glycoprotein Transport of Neurotoxic PesticidesThe use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.What do drug transporters really do?Computational modelling of placental amino acid transfer as an integrated systemThe Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineAbsence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.Compartmental models for apical efflux by P-glycoprotein: part 2--a theoretical study on transporter kinetic parameters.Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.In vitro methods to support transporter evaluation in drug discovery and development.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Membrane Transporters and Pharmacological ImplicationsMechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrierProteoliposomes as tool for assaying membrane transporter functions and interactions with xenobiotics.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simulation.A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.
P2860
Q24273350-8EB5B95E-4F5D-4940-A839-083DC601C9C6Q27023912-F1341B3D-0CF0-48D1-9C79-9EAA4BF4A32BQ28071292-4A88C92C-891D-4EDB-8D81-D3826715792AQ28077066-8C88F017-0DAF-4C53-87DB-E243B77D4545Q28389145-18B8BD1A-6C53-4403-A75A-11769E2734FFQ30670381-95BE1369-CFC5-4259-AD8F-A71166445DB9Q30776360-B307B44E-3025-4DF8-BDA5-2896355BE66EQ35560052-0DBD3DCE-027A-4885-8E0E-147829D1DFBFQ36234390-D4C90294-4CA0-4C7C-B335-DC628D5DD416Q36332525-D83A0438-2D1D-488B-9A18-F9DDB9314FCAQ36571217-6AEB7F16-82B1-4679-A525-7EC34DCF6021Q36945910-31AE9883-7653-405F-9FC0-D455B2048DEFQ37071977-9FCDFD40-31A2-41F1-8533-118FBDC494ACQ37470663-09A72E2B-F596-47CB-AE57-A7ABDDFE354CQ37550693-966019EE-4349-4196-BC15-B9E54C1B4B39Q37595617-4C89409D-D9F2-44A1-899F-36D734C50AB4Q37625260-6BC40DF6-0C72-450D-8B1D-5DA74FE4F9A9Q37726177-06ADAF86-42DE-44DC-B152-F445A98832C0Q38099194-49B92811-32EE-4089-ABA6-AB0EF78B0094Q38200490-62B3A815-FABE-4689-BEA6-530F6E601E29Q38233298-FD03E956-4BB7-4D83-B330-09CD21AFCB18Q38302225-512C12A7-6F17-42AD-9DB0-AE0AE5CBAA95Q38798449-6D53E75D-BB9C-444E-A940-8CFA501EFAC7Q38811728-D50E6A86-BB05-4625-AFF6-EC2E477AF881Q38844656-8203843C-B607-4DD8-A107-5FE06BF3C5DEQ38887625-105DB3FC-1691-43BB-AD98-99AB8B87DE69Q38888355-384707C6-4571-4955-BDF1-DF5BED6881ACQ38888365-7DAA2BE6-29A3-4EC9-A76D-DC66FEC43D51Q38958223-BEC1E3B0-B13C-4C16-9B98-C1A5BFA3B38DQ39178447-58905202-3768-4130-8F50-BC5588EB66BDQ41022921-1E886DC9-DEB2-4C88-8A44-4ACD1BBDF4BCQ41150870-368EB05A-688C-4260-8A10-51BC824517C1Q42177328-63D4E2B5-26B3-4BA6-A86B-D3FDB9F5DEB5Q42484273-A37E4BDE-510C-43E0-B823-0F227F78D7F5Q42873690-8EB358BC-FB42-4B2D-9387-6ED24767390AQ44737065-2619C19B-C3A6-4ECC-8B29-404A92E4D7BCQ45243894-B78FD7D1-4DED-47EC-9B25-060BCBE7D863Q45753948-FAF7CC52-8406-458E-911D-74CCC2CE3591Q47305834-F8762AF6-2058-46AE-98F1-02295E0605A6Q48172902-1AD41066-4182-4E7D-BAD8-D8E1CADE179A
P2860
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
ITC recommendations for transp ...... mediated PK and DDIs in humans
@ast
ITC recommendations for transp ...... mediated PK and DDIs in humans
@en
ITC recommendations for transp ...... mediated PK and DDIs in humans
@nl
type
label
ITC recommendations for transp ...... mediated PK and DDIs in humans
@ast
ITC recommendations for transp ...... mediated PK and DDIs in humans
@en
ITC recommendations for transp ...... mediated PK and DDIs in humans
@nl
prefLabel
ITC recommendations for transp ...... mediated PK and DDIs in humans
@ast
ITC recommendations for transp ...... mediated PK and DDIs in humans
@en
ITC recommendations for transp ...... mediated PK and DDIs in humans
@nl
P2093
P2860
P50
P3181
P356
P1476
ITC recommendations for transp ...... mediated PK and DDIs in humans
@en
P2093
International Transporter Consortium
J C Kalvass
K Korzekwa
M J Zamek-Gliszczynski
P2860
P3181
P356
10.1038/CLPT.2013.45
P407
P577
2013-02-25T00:00:00Z